Aligos Therapeutics Stock Today
| ALGS Stock | USD 17.33 0.49 2.75% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Aligos Therapeutics is selling for under 17.33 as of the 26th of February 2025; that is 2.75 percent decrease since the beginning of the trading day. The stock's lowest day price was 16.02. Aligos Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. The company has 3.46 M outstanding shares of which 576.36 K shares are presently shorted by private and institutional investors with about 1.66 trading days to cover. More on Aligos Therapeutics
Moving together with Aligos Stock
Moving against Aligos Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Aligos Stock Highlights
| President CEO | Dr MBA |
| Old Name | Alon Natural Gas Exploration Ltd |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Aligos Therapeutics (ALGS) is traded on NASDAQ Exchange in USA. It is located in One Corporate Drive, South San Francisco, CA, United States, 94080 and employs 68 people. Aligos Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.94 M. Aligos Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.46 M outstanding shares of which 576.36 K shares are presently shorted by private and institutional investors with about 1.66 trading days to cover.
Aligos Therapeutics currently holds about 159.34 M in cash with (79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check Aligos Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Aligos Therapeutics is $63.94 Million. 30% of Aligos Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Aligos Ownership Details
Aligos Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Aligos Therapeutics market risk premium is the additional return an investor will receive from holding Aligos Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | (0.15) |
Aligos Stock Against Markets
Aligos Therapeutics Corporate Management
| TseI Lin | VP Head | Profile | |
| Leonid Beigelman | Pres Director | Profile | |
| Lucinda JD | Chief VP | Profile | |
| Matthew MD | Executive Officer | Profile | |
| Dr DABT | Executive Sciences | Profile | |
| Kristina Engeseth | Ex Culture | Profile |
Already Invested in Aligos Therapeutics?
The danger of trading Aligos Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aligos Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aligos Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aligos Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.